Judd J et al. reported the relation of irAEs with patient characteristics and outcomes in non-melanoma (head and neck squamous cell carcinoma, non-small cell lung cancer, renal cell carcinoma, and urothelial carcinoma) patients who received the PD-1 checkpoint inhibitors [27]; the ORR was 14% in patients with non-irAEs, 32% in patients with low-grade irAEs. This evidence concerns the gene PDCD1 and melanoma.